Matches in UGent Biblio for { <https://biblio.ugent.be/publication/835705#aggregation> ?p ?o. }
Showing items 1 to 37 of
37
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B190717.
- aggregation creator B190718.
- aggregation creator B190719.
- aggregation creator B190720.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2009".
- aggregation format "application/pdf".
- aggregation hasFormat 835705.bibtex.
- aggregation hasFormat 835705.csv.
- aggregation hasFormat 835705.dc.
- aggregation hasFormat 835705.didl.
- aggregation hasFormat 835705.doc.
- aggregation hasFormat 835705.json.
- aggregation hasFormat 835705.mets.
- aggregation hasFormat 835705.mods.
- aggregation hasFormat 835705.rdf.
- aggregation hasFormat 835705.ris.
- aggregation hasFormat 835705.txt.
- aggregation hasFormat 835705.xls.
- aggregation hasFormat 835705.yaml.
- aggregation isPartOf urn:issn:0021-9541.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Adenovirus-mediated hPNPase(old-35) gene transfer as a therapeutic strategy for neuroblastoma".
- aggregation abstract "Current treatment options for neuroblastoma fail to eradicate the disease in the majority of high-risk patients, clearly mandating development of innovative therapeutic strategies. Gene therapy represents a promising approach for reversing the neoplastic phenotype or driving tumor cells to self-destruction. We presently studied the effects of adenovirus-mediated gene transfer of human polynucleotide phosphorylase (hPNPase(old-35)), a 3',5'-exoribonuclease with growth-inhibitory properties, in neuroblastoma cells. Transgene expression was driven by either the cytomegalovirus (CMV) promoter or by a tumor-selective promoter derived from progression elevated gene-3 (PEG-3). Our data demonstrate that efficient adenoviral transduction of neuroblastoma cells and robust transgene expression are feasible objectives, that the PEG-3 promoter is capable of selectively targeting gene expression in the majority of neuroblastoma cells, and that hPNPase(old-35) induces profound growth suppression and apoptosis of malignant neuroblastoma cells, while exerting limited effects on normal neural crest-derived melanocytes. These findings support future applications of hPNPase(old-35) for targeted gene-based therapy of neuroblastoma and suggest that combination with the PEG-3 promoter holds promise for creating a potent and selective neuroblastoma therapeutic.".
- aggregation authorList BK449510.
- aggregation endPage "715".
- aggregation issue "3".
- aggregation startPage "707".
- aggregation volume "219".
- aggregation aggregates 835706.
- aggregation isDescribedBy 835705.
- aggregation similarTo jcp.21719.
- aggregation similarTo LU-835705.